1. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

    Benzinga – 10:04 AM ET 05/24/2022

    Susquehanna upgraded the previous rating for Lattice Semiconductor Corp from Neutral to Positive. According to Barclays, the prior rating for Otis Worldwide Corp was changed from Equal-Weight to Overweight. B of A Securities upgraded the previous rating for Northwest Natural Holding Co from Underperform to Neutral.

  2. Show article details.

    Horizon Therapeutics plc to Present MIRROR Randomized Controlled Trial Primary Endpoint Data at The EULAR 2022 European Congress of Rheumatology

    Business Wire – 8:00 AM ET 05/24/2022

    -- Oral presentation on KRYSTEXXA® plus methotrexate to be held June 2, 2022 at 11:35 a.m. CEST-- -- Additional data presentations provide new insights on psychosocial and comorbidity impact of gout to help inform evolving treatment strategies -- DUBLIN---- Horizon Therapeutics plc (HZNP) today announced a series of data presentations during The EULAR 2022 European Congress of Rheumatology, June 1 – 4...

  3. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

    Benzinga – 10:33 AM ET 05/23/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  4. Show article details.

    4 Analysts Have This to Say About Horizon Therapeutics

    Benzinga – 9:05 AM ET 05/23/2022

    Horizon Therapeutics has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $127.5 versus the current price of Horizon Therapeutics at $90.35, implying upside. Below is a summary of how these 4 analysts rated Horizon Therapeutics over the past 3 months.

  5. Show article details.

    Horizon Therapeutics Earnings Perspective: Return On Capital Employed

    Benzinga – 9:52 AM ET 05/19/2022

    According to Benzinga Pro, during Q1, Horizon Therapeutics earned $204.26 million, a 17.95% increase from the preceding quarter. Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business.

  6. Show article details.

    Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata

    Benzinga – 9:27 AM ET 05/17/2022

    Horizon Therapeutics plc enrolled first patient in a Phase 2, open-label, proof-of-concept trial of its drug candidate Daxdilimab to treat people with moderate-to-severe alopecia areata. The company is planning to enrol approximately 30 participants in this study. The primary endpoint in this phase of the study is the percent change from baseline in Severity of Alopecia Tool score at Week 24.

  7. Show article details.

    Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (HZN-7734) for the Treatment of Alopecia Areata

    Business Wire – 8:00 AM ET 05/17/2022

    Horizon Therapeutics plc (HZNP) today announced the first patient has enrolled in a Phase 2, open-label, proof-of-concept trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7, to treat people with moderate-to-severe alopecia areata.

  8. Show article details.

    Horizon Therapeutics plc Ranked Second in Overall Corporate Reputation in U.S. PatientView Survey of Patient Groups

    Business Wire – 9:00 AM ET 05/16/2022

    Among patient groups familiar with Horizon, the company ranked first in patient group relationships, integrity, services beyond the pill and patient centricity Horizon Therapeutics plc (HZNP) today announced that it ranked second in overall corporate reputation among U.S. patient groups who were familiar with the company and third among groups who reported working with the company.

  9. Show article details.

    Horizon Therapeutics plc Announces Dara Mann as a Healthcare Businesswomen’s Association 2022 Rising Star

    Business Wire – 9:02 AM ET 05/11/2022

    Horizon Therapeutics plc (HZNP) today announced that Dara Mann, vice president, marketing, ophthalmology, has been named a 2022 Healthcare Businesswomen’s Association Rising Star. The HBA is the leading nonprofit global organization committed to furthering the advancement and impact of women in health care.

  10. Show article details.

    Horizon Therapeutics plc Launches Letter-Writing Campaign to Empower Those Living with Thyroid Eye Disease (TED) to Confront the Condition Head On

    Business Wire – 8:30 AM ET 05/11/2022

    -- Nationwide campaign spotlights mental health impact of living with TED -- For Mental Health Awareness Month and Healthy Vision Month in May, Horizon Therapeutics plc (HZNP) is partnering with mental health expert and New York Times best-selling author, Lori Gottlieb, to highlight the emotional burden of living with TED – a serious, progressive, and potentially vision-threatening rare autoimmune con...

  11. Show article details.

    BRIEF-Horizon Therapeutics And Chicago Sky Announce Multi-Year Partnership

    Reuters – 4:46 PM ET 05/09/2022

    Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS AND CHICAGO SKY ANNOUNCE MULTI-YEAR PARTNERSHIP. * Horizon Therapeutics PLC (HZNP) - PARTNERSHIP MAKES HORIZON OFFICIAL AND EXCLUSIVE BIOTECH PARTNER OF CHICAGO SKY AND INCLUDES COMMUNITY PROGRAMMING Source text for Eikon: Further company coverage:

  12. Show article details.

    Horizon Therapeutics and Chicago Sky Announce Multi-Year Partnership

    Business Wire – 4:44 PM ET 05/09/2022

    - Partnership Makes Horizon the Official and Exclusive Biotech Partner of the Chicago Sky and Includes Community Programming - Horizon Therapeutics (HZNP) and the Chicago Sky today announced a multi-year partnership, which includes robust community programming as well as marketing and branding assets.

  13. Show article details.

    Horizon Therapeutics: Q1 Earnings Insights

    Benzinga – 8:27 AM ET 05/04/2022

      Horizon Therapeutics reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Horizon Therapeutics beat estimated earnings by 11.67%, reporting an EPS of $1.34 versus an estimate of $1.2. Revenue was up $542.84 million from the same period last year.

  14. Show article details.

    Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results

    Business Wire – 7:00 AM ET 05/04/2022

    First-Quarter 2022 Results: -- Net Sales of $885.2 Million -- -- GAAP Net Income of $204.3 Million; Adjusted EBITDA of $371.2 Million -- -- TEPEZZA® Net Sales of $501.5 Million -- -- KRYSTEXXA® Net Sales of $140.7 Million -- -- Cash Position of $1.64 Billion as of March 31, 2022 -- Full-Year 2022 Guidance: -- Maintaining Full-Year 2022 Net Sales Guidance of $3.9 Billion to $4.0 Billion, Represe...

  15. Show article details.

    Earnings Scheduled For May 4, 2022

    Benzinga – 4:36 AM ET 05/04/2022

      ** Seres Therapeutics is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million. ** Obsidian Energy is projected to report quarterly earnings at $0.41 per share on revenue of $156.00 million. ** International Seaways is estimated to report quarterly loss at $0.31 per share on revenue of $96.75 million.

  16. Show article details.

    Topline Data for Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis

    Business Wire – 9:15 AM ET 05/03/2022

    Detailed results to be presented at upcoming medical congress Horizon Therapeutics plc (HZNP) today announced that its Phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep in rheumatoid arthritis met the primary endpoint.

  17. Show article details.

    Horizon Therapeutics plc Launches #RAREis Global Advocate Grant Program to Support the Rare Disease Community

    Business Wire – 4:05 PM ET 05/02/2022

    Horizon Therapeutics plc (HZNP) today announced the launch of the #RAREis Global Advocate Grant, a new program designed to support the rare disease community by providing financial assistance to U.S. and global patient advocacy groups working to advance, educate and address the needs of the community.

  18. Show article details.

    Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

    Benzinga – 1:09 PM ET 05/02/2022

    Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

  19. Show article details.

    BRIEF-Horizon Therapeutics Says Received European Commission Approval Of Uplizna

    Reuters – 1:05 AM ET 05/02/2022

    Horizon Therapeutics PLC (HZNP): * HORIZON THERAPEUTICS PLC RECEIVES EUROPEAN COMMISSION APPROVAL OF UPLIZNA® FOR THE TREATMENT OF ADULTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDER. * HORIZON THERAPEUTICS (HZNP) - EC APPROVAL SUPPORTED BY RESULTS FROM N-MOMEMTUM, SHOWED 87.6% OF AQP4-IGG+ NMOSD PATIENTS ON UPLIZNA WERE ATTACK FREE FOR 28 WEEKS Source text for Eikon: Further company coverage:

  20. Show article details.

    Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD)

    Business Wire – 1:00 AM ET 05/02/2022

    -- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for treatment of adult patients with NMOSD who are anti-aquaporin-4 immunoglobulin G seropositive, which represents 80% of NMOSD patients -- -- EC approval was supported by results from N-MOmemtum, the la...

Page:

Today's and Upcoming Events

  • Aug
    03

    HZNP to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    04

    HZNP announced Q1 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.